A titratable, fixed ratio combination of two well understood and FDA approved peptides to control glycemia while mitigating the threat of hypoglycemia.
The Challenge: Balancing Diabetes Control and Hypoglycemia Risk
Insulin remains the mainstay for glycemic control for patients with Type 1 diabetes and for people with Type 2 diabetes not controlled on non-insulin therapies
Hypoglycemia, and the fear of it, remain the primary impediments to achieving target glycemic control
The majority of patients on insulin do not achieve their A1C targets
Severe hypoglycemia continues to result in high direct medical costs and lost productivity
ABV100: A smart solution that fits well with current and future pharmacological and device platforms.
